-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text|Pharmaceutical Mission Hills
Today, Enomicro Pharmaceuticals announced that its self-developed product MVR-C5252 for malignant glioma has been approved by the US FDA for clinical research
.
Just last Friday, the company's herpes oncolytic virus intravenous drug product MVR-T3011 IV (intravenous injection) was also approved by China's National Food and Drug Administration (NMPA) to enter the clinical phase
1.
MVR-C5252 indications: Malignant glioma MVR-C5252 is a product specially designed for the treatment of malignant glioma
.
After being approved for clinical use in the United States, its phase 1 clinical trials will be carried out in six clinical institutions including Memorial Sloan Kettering Cancer Center and Duke University
2.
MVR-T3011 IV indications: advanced solid tumor or lymphoma MVR-T3011 (also known as T3011) is a three-in-one herpes oncolytic virus innovative product with independent intellectual property rights of Innomicro.
The virus design concept is derived from The company's innovative and unique insights on herpes virus and genetic modification technology
.
According to the announcement of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration, the product was approved for clinical use in China this time, and it is planned to be developed for intravenous administration to treat patients with advanced solid tumors or lymphomas without effective treatment
Screenshot source: CDE official website
For herpes oncolytic viruses and oncolytic viruses of many other types of viral vectors, the development of intravenous injection has long been a major challenge
.
Most oncolytic viruses cannot overcome many obstacles including being neutralized and cleared by antibodies.
Public information shows that MVR-T3011 through a new design of the wild HSV-I herpes virus skeleton, while achieving the best attenuation effect, while ensuring the virus replication ability in tumor cells and safety to normal cells, it is expected to be achieved A breakthrough in the field of intravenous injection of herpes oncolytic virus
.
In addition, the virus carries the fully verified exogenous immune regulatory genes PD1 antibody and IL12, which are designed to synergistically improve anti-tumor ability and promote the immune response of the tumor microenvironment
Reference materials:
[1] Innomicro Medicine's MVR-C5252 was approved by the FDA to carry out clinical trials for malignant glioma.
